How close is a cure for multiple myeloma?
Substantial advances in the treatment of multiple myeloma over the last decade, attributable to novel agents and novel combinations, are leading investigators to challenge the long-standing belief that myeloma is incurable. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses cure as a goal of therapy rather than disease control, and reinforces the concept of operational cure. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Видео How close is a cure for multiple myeloma? канала VJHemOnc – Video Journal of Hematology & HemOnc
Видео How close is a cure for multiple myeloma? канала VJHemOnc – Video Journal of Hematology & HemOnc
Показать
Комментарии отсутствуют
Информация о видео
7 мая 2021 г. 16:19:24
00:02:38
Другие видео канала
![POLARIX: Polatuzumab vedotin and R-CHP superior to R-CHOP in DLBCL](https://i.ytimg.com/vi/v_qk34yLCgE/default.jpg)
![Results from a Phase II trial of pirtobrutinib, venetoclax, and obinutuzumab in CLL](https://i.ytimg.com/vi/ArbZO-4-M2I/default.jpg)
![Choosing between isatuximab & daratumumab in multiple myeloma](https://i.ytimg.com/vi/jsSam6N0_Zk/default.jpg)
![Defining precursor states in multiple myeloma](https://i.ytimg.com/vi/U-Hm6bIkVdQ/default.jpg)
![Momelotinib: a promising drug for patients with myelofibrosis](https://i.ytimg.com/vi/tGT-g_Vvk2U/default.jpg)
![The promise of mutant CALR antibodies for the treatment of MPNs](https://i.ytimg.com/vi/sX8IRFFRatk/default.jpg)
![IPSS-R vs IPSS-M for MDS](https://i.ytimg.com/vi/yDxeDWJonYY/default.jpg)
![MRD Focus: why measurable residual disease testing is the future](https://i.ytimg.com/vi/fmUmVdKJRnQ/default.jpg)
![Updates from a Phase I study evaluating dendritic cell therapy, cryosurgery & pembrolizumab in NHL](https://i.ytimg.com/vi/tTTgqdy03pw/default.jpg)
![SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia](https://i.ytimg.com/vi/vEHc35KiGqk/default.jpg)
![Investigating melflufen: a peptidase enhanced cytotoxic for myeloma](https://i.ytimg.com/vi/zQ4zoZ9QYIk/default.jpg)
![Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLL](https://i.ytimg.com/vi/bk3k1KzGt5U/default.jpg)
![GENESIS: Motixafortide prior to HCT in patients with MM](https://i.ytimg.com/vi/PF60frOWc7k/default.jpg)
![Mosunetuzumab in the treatment of HCL: a case study](https://i.ytimg.com/vi/vpkUUgjCV9U/default.jpg)
![Subcutaneous ravulizumab trial for paroxysmal nocturnal hemoglobinuria treatment](https://i.ytimg.com/vi/2Zfp5xb7M_g/default.jpg)
![Approval of teclistamab in triple-class refractory multiple myeloma](https://i.ytimg.com/vi/YZ1ywvgos5w/default.jpg)
![Low-dose gemcitabine for advanced CTCL](https://i.ytimg.com/vi/K7yik8yKl2g/default.jpg)
![Evolving CLL treatments: creating choices and igniting discussions](https://i.ytimg.com/vi/F-ipWvxeldY/default.jpg)
![An insight into Langerhans cell histiocytosis and advances in treatment approaches](https://i.ytimg.com/vi/PExJ-gNjZHM/default.jpg)
![The importance of improving immune function in CLL](https://i.ytimg.com/vi/opgYd4Imdpo/default.jpg)
![Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma](https://i.ytimg.com/vi/s5c6zpimwXY/default.jpg)